Full text is available at the source.
Abstract
Among 398,470 Medicare beneficiaries, once-weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were associated with a reduced risk of cardiovascular events compared to other non-insulin glucose lowering therapies.
- Once-weekly GLP-1 RAs showed a hazard ratio range of 0.72 to 0.88 for cardiovascular events, indicating a lower risk compared to other treatments.
- Patients treated with GLP-1 RAs experienced lower healthcare resource utilization, with a 9% reduction in total medical visits related to atherosclerotic cardiovascular disease.
- Total medical costs were also reduced by 12% among those using GLP-1 RAs compared to other therapies.
- Semaglutide, a specific GLP-1 RA, demonstrated the lowest risk of cardiovascular outcomes when compared to SGLT2 inhibitors and DPP-4 inhibitors.
Simplified